ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $248 | +78.4% | 14,243 | +221.5% | 0.01% | 0.0% |
| Q4 2023 | $139 | +15.8% | 4,430 | -23.4% | 0.01% | +20.0% |
| Q3 2023 | $120 | -14.9% | 5,781 | -1.5% | 0.01% | -16.7% |
| Q2 2023 | $141 | +27.0% | 5,869 | -0.5% | 0.01% | +20.0% |
| Q1 2023 | $111 | +18.1% | 5,901 | -0.3% | 0.01% | +25.0% |
| Q4 2022 | $94 | -99.9% | 5,921 | -16.3% | 0.00% | -20.0% |
| Q3 2022 | $116,000 | -7.9% | 7,073 | -21.1% | 0.01% | +25.0% |
| Q2 2022 | $126,000 | +20.0% | 8,959 | +107.1% | 0.00% | +100.0% |
| Q1 2022 | $105,000 | -9.5% | 4,326 | -13.1% | 0.00% | 0.0% |
| Q4 2021 | $116,000 | +38.1% | 4,979 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $84,000 | -34.4% | 5,061 | -3.8% | 0.00% | 0.0% |
| Q2 2021 | $128,000 | -5.9% | 5,261 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $136,000 | -76.0% | 5,261 | -50.3% | 0.00% | -75.0% |
| Q4 2020 | $566,000 | +4.2% | 10,583 | -19.7% | 0.01% | -7.7% |
| Q3 2020 | $543,000 | -15.0% | 13,174 | 0.0% | 0.01% | -18.8% |
| Q2 2020 | $639,000 | +13.5% | 13,174 | -1.1% | 0.02% | 0.0% |
| Q1 2020 | $563,000 | -2.8% | 13,322 | -1.5% | 0.02% | +33.3% |
| Q4 2019 | $579,000 | +16.5% | 13,525 | -2.1% | 0.01% | +9.1% |
| Q3 2019 | $497,000 | +33.2% | 13,821 | -0.9% | 0.01% | +37.5% |
| Q2 2019 | $373,000 | -2.6% | 13,940 | -2.2% | 0.01% | 0.0% |
| Q1 2019 | $383,000 | +65.8% | 14,259 | 0.0% | 0.01% | +33.3% |
| Q4 2018 | $231,000 | -28.0% | 14,259 | -7.8% | 0.01% | 0.0% |
| Q3 2018 | $321,000 | +36.0% | 15,459 | 0.0% | 0.01% | +20.0% |
| Q2 2018 | $236,000 | -35.7% | 15,459 | -5.3% | 0.01% | -28.6% |
| Q1 2018 | $367,000 | -25.4% | 16,332 | 0.0% | 0.01% | -30.0% |
| Q4 2017 | $492,000 | +51.9% | 16,332 | +40.5% | 0.01% | +42.9% |
| Q2 2017 | $324,000 | -19.0% | 11,622 | 0.0% | 0.01% | -22.2% |
| Q1 2017 | $400,000 | -16.5% | 11,622 | -30.0% | 0.01% | -18.2% |
| Q4 2016 | $479,000 | -55.2% | 16,610 | -50.6% | 0.01% | -50.0% |
| Q3 2016 | $1,070,000 | – | 33,644 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
| GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
| Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
| Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
| Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
| SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
| Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
| Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
| PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |